|Bid||37.06 x 3200|
|Ask||37.07 x 1200|
|Day's Range||37.05 - 37.32|
|52 Week Range||30.20 - 39.18|
|PE Ratio (TTM)||161.22|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / QIAGEN NV (NYSE: QGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 9:00:00 AM Eastern Time. To listen ...
Day-one lab readiness speeds commercialization and reimbursement in personalized medicine
Frankfurt Prime Standard: QIA) today announced that its careHPV™ Test, one of the only molecular diagnostics for high-risk human papillomavirus (HPV) designed to screen women in low-resource settings, has been added to the World Health Organization (WHO) list of prequalified in vitro diagnostics (IVDs). HPV is the primary cause of cervical cancer, so screening women for the presence of the virus is a critical aspect for prevention and early treatment of the deadly cancer.
Collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB detection
QIAGEN N.V. plans as previously announced to release its report on results for the second quarter 2018 on Tuesday, July 31 shortly after 22:00 Central European Time / 16:00 Eastern Daylight Time .
QIAGEN N.V. today introduced seamless next-generation sequencing solutions for a wide range of hereditary diseases on the GeneReader NGS System, the complete Sample to Insight NGS solution for any lab worldwide.
WallStEquities.com has initiated research reports on the following Services stocks: CareDx Inc. (CDNA), Myriad Genetics Inc. (MYGN), QIAGEN N.V. (QGEN), and Nxt-ID Inc. (NXTD). Brisbane, California headquartered CareDx Inc.'s stock finished Wednesday's session 5.51% lower at $14.74 with a total trading volume of 569,113 shares, which was higher than their three months average volume of 518.93 thousand shares. The Company's shares are trading above their 50-day and 200-day moving averages by 26.99% and 101.82%, respectively.
QIAGEN N.V. today announced that it welcomes new guidelines from the American Academy of Pediatrics that recommend screening at-risk children as young as two years old for latent tuberculosis infection.
QIAGEN N.V. today announced a partnership with Freenome, a leading artificial intelligence genomics company, to accelerate the development and commercialization of next-generation sequencing tests to enable precision medicine in cancer treatment.
QIAGEN today welcomed the First Edition of the World Health Organization’s (WHO) Essential Diagnostics List, which endorses the use of interferon gamma release assays (IGRAs) for the diagnosis of latent TB infection. The inclusion on the list comes as the WHO and other organizations like the US Centers for Disease Control (CDC), the International Panel Physicians Association (IPPA) and others have recommended to include IGRA’s such as QuantiFERON-TB Gold Plus. The World Health Organization (WHO) published the first edition of the Model List of Essential In Vitro Diagnostics (EDL) in May 2018, in recognition that IVDs are an essential component to advance universal health coverage, address health emergencies, and promote healthier populations.
On Tuesday, May 15, 2018, US markets saw broad based losses with all sectors finishing the trading sessions in red. All you have to do is sign up today for this free limited time offer by clicking the link below.
Frankfurt Prime Standard: QIA) announces that it will initiate the repurchase of a first tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between May 15, 2018 until August 20, 2018, at the latest, a first tranche of up to 1.65 million common shares of the Company having a total purchase price of up to USD 50 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.
QIAGEN N.V. announced results of operations for the first quarter, exceeding goals for net sales and adjusted earnings per share while driving global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.
QIAGEN N.V. today announced the U.S. regulatory approval of PartoSureTM , which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.
QIAGEN N.V. today announced the launch of QIAstat-Dx® in Europe, providing a one-step, fully integrated molecular analysis of common syndromes as tested for in syndromes in infections, oncology and other diseases.
QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2018 on Wednesday, May 2 shortly after 22:00 Central European Time / 16:00 Eastern Daylight Time .
QIAGEN N.V. today launched two novel liquid biopsy panels to evaluate circulating tumor cells in the growing field of research into molecular mechanisms in prostate and lung cancers.
QIAGEN N.V. announced today that its QuantiFERON-TB® Gold Plus , the gold standard in accurate, cost-effective testing for latent tuberculosis infection, has been endorsed for immigration medical screening by the International Panel Physicians Association .
Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge, cell-free DNA assays for use on QIAGEN's GeneReader NGS System. Natera's Constellation™ software would also be accessible for users of these and other assays in combination with the QIAGEN Clinical Insights (QCI) bioinformatics solution.
QIAGEN N.V. , a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. , a leading developer of next-generation sequencing assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System.
QIAGEN N.V. today endorsed new guidelines issued by the World Health Organization , which coordinates global efforts to control tuberculosis , calling for harmonization of preventive screening and treatment of latent TB infection among vulnerable groups in countries with a high disease burden, as well as in low-burden countries.
QIAGEN N.V. announced today that it welcomed a decision by the U.S. Centers for Disease control to require the use of modern blood-based tests for tuberculosis screening.